Investigating the effects of MMS22L loss and PARP inhibitors in prostate cancer
MMS22L loss and PARP inhibition in prostate cancer
This study is exploring how to create personalized treatments for men with advanced prostate cancer by looking at their tumor's genes, especially those related to DNA repair, to see who might benefit most from a specific type of medication called PARP inhibitors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11052649 on NIH RePORTER |
What this research studies
This research focuses on metastatic castration-resistant prostate cancer (mCRPC), a challenging condition with limited treatment options. It aims to develop personalized therapies based on genomic alterations in tumors, particularly looking at how defects in DNA damage response genes like BRCA1 and BRCA2 affect treatment outcomes. By using PARP inhibitors, which target cancer cells that cannot repair their DNA effectively, the study seeks to identify which patients are most likely to benefit from these therapies. The approach involves analyzing genetic markers to tailor treatments to individual patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic castration-resistant prostate cancer, particularly those with BRCA1 or BRCA2 mutations.
Not a fit: Patients with early-stage prostate cancer or those without specific genetic mutations related to DNA damage response may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results with PARP inhibitors in similar patient populations, indicating a potential for success in this approach.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Jia, Li — Brigham and Women's Hospital
- Study coordinator: Jia, Li
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.